Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma

The complete remission (CR) rate achieved with induction chemotherapy prior to autologous stem cell transplantation (ASCT) represents the strongest prognostic factor in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). By inducing a CR rate of 75%, the bendamustine, gemcitabine, vinorelbin...

詳細記述

保存先:
書誌詳細
出版年:Blood Adv
主要な著者: Santoro, Armando, Mazza, Rita, Pulsoni, Alessandro, Re, Alessandro, Bonfichi, Maurizio, Zilioli, Vittorio Ruggero, Zanni, Manuela, Merli, Francesco, Anastasia, Antonella, Luminari, Stefano, Annechini, Giorgia, Gotti, Manuel, Peli, Annalisa, Liberati, Anna Marina, Di Renzo, Nicola, Castagna, Luca, Giordano, Laura, Ricci, Francesca, Carlo-Stella, Carmelo
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2020
主題:
Clinical Trials and Observations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6960479/
https://ncbi.nlm.nih.gov/pubmed/31935284
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000984
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料